Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer

28 Oct 2021

Abstract excerpt

Dysregulation of the cell cycle machinery leads to genomic instability and is a hallmark of cancer associated with chemoresistance and poor prognosis in colorectal cancer (CRC). Identifying and targeting aberrant cell cycle machinery is expected to improve current therapies for CRC patients. Here,upregulated polo-like kinase 1 (PLK1) signaling, accompanied by deregulation of cell cycle-related pathways in CRC is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Genetic factors in colorectal cancer
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34881526
DOI: 10.1002/advs.202100759

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal CancerPMID 34881526Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer ManagementSemantic proximity Read ↗

PLK4 is a key molecule in the formation of PGCCs and promotes invasion and migration of progeny cells derived from PGCCsSemantic proximity Read ↗

Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancerSemantic proximity Read ↗

PDK1 Signaling Toward PLK1–MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted TherapySemantic proximity Read ↗

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read ↗

PLK4: a link between centriole biogenesis and cancerSemantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

Loss of <i>UBP1</i> drives oxaliplatin resistance through a targetable dependency on translation initiationSemantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

RPL27 contributes to colorectal cancer proliferation and stemness via PLK1 signalingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.